Abstract-Platelet hyperactivity associated with hyperlipidemia may contribute to development of a prothrombotic state.We previously showed that oxidized low-density lipoprotein (oxLDL) formed in the setting of hyperlipidemia and atherosclerosis activated platelets in a CD36-dependent manner. We now show that mitogen-activated protein kinase c-Jun N-terminal kinase (JNK)2 and its upstream activator MKK4 were phosphorylated in platelets exposed to oxLDL. Using apoE Ϫ/Ϫ mice as a model of hyperlipidemia, we showed that JNK was constitutively phosphorylated in platelets in a CD36-dependent manner. Inhibition of src kinase activity reduced JNK phosphorylation by oxLDL. Immunoprecipitations revealed that active phosphorylated forms of src kinases Fyn and Lyn were recruited to CD36 in platelets exposed to oxLDL. Pharmacological inhibition of the mitogen-activated protein kinase JNK or src family kinases abolished platelet activation by oxLDL in vitro. Using a murine carotid artery thrombosis model we demonstrated CD36-dependent phosphorylation of platelet JNK within thrombi. Furthermore, pharmacological inhibition of JNK prolonged thrombosis times in wild-type but not cd36-null mice in vivo. These findings suggest that a specific CD36-dependent signaling pathway is required for platelet activation by oxLDL and may provide insights related to development of novel antiplatelet therapies more relevant to atherothrombosis than to normal hemostasis. (Circ Res.
2008;102:1512-1519.)Key Words: CD36 Ⅲ JNK Ⅲ thrombosis Ⅲ hyperlipidemia C D36 is an integral membrane protein expressed on monocytes/macrophages, 1 platelets, 2 microvascular endothelium, 1 fat, and muscle. 3,4 Although initially identified as a receptor for thrombospondin-1 and malaria-infected erythrocytes, 5,6 it is now known to be a class B scavenger receptor that recognizes several unrelated ligands, including thrombospondin-1 and -2, 7,8 oxidized phospholipids expressed on oxidized low-density lipoprotein (oxLDL) and apoptotic cell surfaces, 9,10 long chain fatty acids, 11 amyloidogenic peptides, 12 and specific components of microbial cell walls or cell surfaces. 13 CD36 is involved in a variety of biological processes including lipid metabolism, inflammation, atherosclerosis, and angiogenesis, depending on the nature of the ligand to which it is exposed and the cell or tissue type on which it is expressed. 14 Although CD36 was first isolated and structurally characterized from platelets, 2 its functional role on platelets remains incompletely characterized. OKM5, a monoclonal antibody directed against CD36, was observed many years ago to induce platelet activation and aggregation. 15 Although the effect was dependent on expression of Fc receptors, it could be blocked by F(abЈ) 2 fragments of the antibody, suggesting that the CD36 epitope was required and that CD36 may transduce platelet activating signals. Many other CD36 monoclonal antibodies have also been shown to have stimulatory effects on platelets. 16 Our group in collaboration with others recently sho...